ArticleMikrochimica acta2025
Enzyme-free quantification of breast cancer-derived exosomes via cubic DNA nanostructure-enhanced hybridization chain reaction.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast tumor-derived exosomes promise to guide diagnosis and therapy. But the small size and low mass of exosomes have higher requirements for target binding and signal amplification. Although hybridization chain reaction (HCR) has been extensively utilized for the sensitive detection of an enormous range of biomolecules, including the exosomes, achieving sufficient amplification efficiency remains challenging. To address this limitation, more and more researchers integrate the reaction system with functional materials of DNA. Inspired by this, we herein report for the first time the cubic DNA nanostructure enhanced hybridization chain reaction (CDN-HCR) to detect breast tumor-derived exosomes. Unlike other nanostructure-assisted HCR approaches, the four cholesterol anchors on the CDN enhance the binding affinity of signal probes for exosomes, while the four triggers combined with the supporting CDN further improve the reaction efficiency of HCR. Furthermore, incorporating an electrochemical detection system, the assay platform enables enzyme-free and label-free detection of exosomes. The quantitative detection of exosomes is easily achieved with a linear range of 5.5 × 10
Indexed as
Identifiers
41026304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.